Michael B. Atkins, MD, reviews a case involving a female patient who was diagnosed with stage IV BRAF-mutated melanoma, and shares insights on the patient’s prognosis and his approach to diagnosis.
Case: A 62-Year-Old Female with Stage IV Melanoma
This is a video synopsis/summary of a Case-Based Peer Perspectives episodefeaturing Michael B. Atkins, MD.
A 62-year-old woman presented to her dermatologist for removal of a pigmented lesion on her shoulder that had recently become darker. She reported experiencing persistent fatigue, shortness of breath, and a dry cough that she attributed to prior COVID-19 infection. Her lactate dehydrogenase level was 174 U/L, which is within normal range. An excisional biopsy of the shoulder lesion revealed a melanoma with a Breslow thickness of 1.2 mm; it was ulcerated and had a high mitotic rate. She underwent wide local excision and sentinel lymph node mapping, which showed melanoma metastasis in a right axillary sentinel lymph node. A CT of the chest, abdomen, and pelvis showed multiple lung lesions. A core needle biopsy of the largest lung lesion revealed melanoma with a positive BRAF V600E mutation. A brain MRI showed no metastases. Her ECOG performance status was 1 due to fatigue and cough. She received a diagnosis of stage IV melanoma, T2b, N1a, M1b.
Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.
Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4
July 16th 2024During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the second article of a 2-part series.
Read More